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cetani@endoc.med.unipi.itAbstractInactivating germline mutations of the CDKN1B gene encoding the nuclear cyclin-
dependent kinase inhibitor P27kip1 protein have been reported in patients with multiple
endocrine neoplasia type 4 (MEN4), a MEN1-like phenotype without MEN1 mutations. The
aim of this study was to characterize in vitro the germline CDKN1B mutation c.374_375delCT
(S125X) we detected in a patient with MEN4. The proband was affected by primary
hyperparathyroidism due to multiglandular parathyroid involvement and gastro–entero–
pancreatic tumors. We carried out subcellular localization experiments by transfection with
plasmid vectors expressing the WT or mutant CDKN1B cDNA into the eukaryotic human
cervix adenocarcinoma (HeLa) and GH3 cell lines. Results from western blotting studies
indicated that fusion proteins were expressed at equal levels. The mutated protein was
shorter compared with the WT protein and lacked the highly conserved C-terminal domain,
which includes the bipartite nuclear localization signal at amino acids 152/153 and 166/168.
In HeLa and GH3 cells, WT P27 localized in the nucleus, whereas the P27_S125X protein was
retained in the cytoplasm, predicting the loss of tumor-suppressive function. The proband’s
tumoral parathyroid tissue did not show allelic loss, because both WT and mutant alleles
were determined to be present by sequencing the somatic DNA. Immunohistochemistry
revealed a complete loss of nuclear expression of P27 in a parathyroid adenoma, which had
been removed by the second surgery in the patient. In conclusion, our results confirm the
pathogenic role of the c.374_375delCT CDKN1B germline mutation in a patient with MEN4.Key Words
" primary hyperparathyroidism
" parathyroid tumorigenesis
" MEN1
" P27icen
.0 UEndocrine Connections
(2015) 4, 1–8sed under a Creative Commons
nported License.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Research E Pardi et al. CDKN1B mutation in MEN4
kindred
2–8 4 :2IntroductionMultiple endocrine neoplasia type 1 (MEN1, OMIM
#131100) is a rare autosomal dominant endocrine disorder
characterized by the occurrence of parathyroid adenoma/
hyperplasia, duodeno–pancreatic neuroendocrine tumors
(NETs), and anterior pituitary tumors in the same
individual (1). A minority of affected patients may also
develop a wide spectrum of endocrine and non-endocrine
manifestations, such as adrenal cortical tumors, foregut
carcinoid tumors, angiofibromas, collagenomas, and
lipomas, thus contributing to the heterogeneity of the
phenotypic presentation. The rare combinations of less
common manifestations of MEN1 are known as ‘pheno-
copy variants’ (2).
Germline heterozygous loss-of-function mutations of
the tumor suppressor MEN1 gene – the main molecular
defect causing the MEN1 syndrome – have been detected
in about 70–80% and 30% of patients with familial and
sporadic MEN1 respectively (3). The percentage in familial
MEN1 rises to 90% if a search for large germline deletions
is performed (4, 5, 6). Thus, a definite proportion of
familial and sporadic MEN1 patients do not carry MEN1
mutations, indicating that other tumor-susceptibility
genes may be involved in the pathogenesis of this
syndrome. Following the identification of a germline
change in the cyclin-dependent kinase (CDK) inhibitor
Cdkn1b gene as the causative mutation of a variant of both
MEN1 and MEN2 human syndromes in a rat colony
(MENX syndrome), mutations of the human homologue
CDKN1B were searched for in individuals with the MEN1
clinical phenotype, but withoutMEN1mutations (7). Nine
different germline mutations in the coding, as well as in
the 5 0-UTR of the CDKN1B gene have been described in
patients with familial or sporadic MEN1-like syndromes,
but negative for MEN1 mutations (7, 8, 9, 10, 11, 12, 13).
Results from in vitro studies have confirmed the patho-
genic role of these mutations (14).
The cases with mutations of CDKN1B are now
classified as having the MEN4 syndrome (OMIM
#610755), although they do not have any peculiar
phenotypic manifestations compared with MEN1-
mutation-positive cases. However, given the small number
of reported MEN4 patients, the clinical penetrance of the
disease and the precise tumor spectrum of the syndrome
are still to be defined.
The CDKN1B gene encodes a nuclear protein named
P27 (also known as KIP1), a member of the CDK inhibitors
family. P27 regulates the transition of G1 phase to S phase
by inhibiting the activity of CDKs and by promoting exithttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0116
 2015 The authors
Published by Bioscientifica Ltdfrom the cell cycle. The subcellular localization of P27
appears to be central to regulation of its function. The
antiproliferative role of P27 depends on its presence in the
nucleus, the cellular compartment where it complexes
with its target kinases (cyclin E-CDK2 and cyclin A-CDK2).
Conversely, in the cytoplasm, despite being deprived
of its tumor suppressor role, P27 drives pro-oncogenic
functions, such as apoptosis and cell motility, and
promotes cell proliferation by complexing to cyclin
D/CDK4,6 (15, 16). P27 harbors a CDK-binding domain
in the N-terminal half of the protein, which is necessary
for the mediation of the CDK-inhibitory functions.
Moreover, P27 contains a bipartite nuclear localization
signal (NLS) at amino acids 152/153 and 166/168 in
its C-terminal part. Although CDKN1B is considered to
be a tumor suppressor gene, somatic loss-of-function
mutations in this gene have rarely been detected in
different cancers (17, 18, 19). Conversely, loss or decreased
expression of the P27 protein has been reported in many
human cancers, where it is often associated with a poor
prognosis (20). Transcriptional, translational, and post-
translational modifications of P27 (i.e., phosphorylation
events), leading to mis-localization and/or sequestration
of the P27 protein in the cytoplasm and subsequent
degradation of the protein by proteasome-dependent
mechanisms, account for the loss of its physiological role
in the control of the cell cycle (21, 22). Nonetheless,
biallelic inactivation of CDKN1B is a rare event, suggesting
that haploinsufficiency may explain the tumorigenic
progression (23, 24, 25, 26). The CDKN1B gene is therefore
considered to be an atypical tumor suppressor gene.
We previously reported a novel loss-of-function
mutation of the CDKN1B gene detected in a Sardinian
kindred with MEN4 (27, 28). The index case was later seen
elsewhere and the detailed description of the patient
has been recently published (29). Herein, we extend the
genetic analysis and describe the functional character-
ization of the mutation.Materials and methods
Informed consent was obtained from the patient and one
of the proband’s three sons for all procedures used in this
study. Our internal review board approved the study.
Tissue samples
Formalin-fixed paraffin embedded (FFPE) parathyroid
tissue (superior right gland) removed at the secondThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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3–8 4 :3parathyroid surgery was retrieved from pathological
archives.
Genetic studies
DNA was extracted from index patient’s peripheral
leukocytes with a Maxwell 16 Instrument according to
the manufacturer’s instructions (Promega Corp.). FFPE
tissues were manually microdissected from two sections
and samples were submitted to xylene deparaffination and
then lysed and digested with proteinase K. DNA extraction
was performed using the spin column procedure (QIAmp
minikit; Qiagen). As no mutations in MEN1 were
identified, the genetic analysis of the coding region and
intron/exon boundaries of the CDKN1B (NM_004064.3)
gene was carried out using the BigDye Sequencing
Reaction Kit v.1.1. The reaction products were separated
on an ABI 3130XL automatic sequencer (Applied Bio-
systems). To assess for loss-of-heterozigosity (LOH), the
fragment of interest in the tumoral DNA was sequenced.Immunohistochemistry
The immunohistochemical analysis was performed using
the avidin–biotin–peroxidase complex method with the
Ventana Benchmark immunostaining system (Ventana
Medical System, Tucson, AZ, USA) following the manu-
facturer’s instructions. A monoclonal anti-P27 antibody
(clone SX53G, Ventana Medical System) was used to
detect expression of P27. A negative control was included
in the analysis by omitting the primary antibody. For the
assessment of immunoreactivity, at least ten randomly
selected fields under high-power magnification (!20)
were chosen. In each experiment, adjacent normal
parenchyma and/or infiltrating lymphocytes served as
an internal positive control. Two specimens of normal
parathyroid gland, inadvertently removed from normo-
calcemic subjects undergoing surgery for nontoxic
multinodular goiter, were also used as controls. The cells
were scored as positive if specific nuclear staining was
detected, independently of the intensity of staining.
Tumor staining was quantified according to the percen-
tage of cells showing specific nuclear staining.Transfection studies
The CDKN1B mutation identified in the proband by
sequencing was introduced by site-directed mutagenesis
(Quikchange II Site-Directed Mutagenesis Kit, Stratagene,
La Jolla, CA, USA) into the full-length WT humanCDKN1B
cDNA cloned in a pEYFP (EYFP, enhanced yellowhttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0116
 2015 The authors
Published by Bioscientifica Ltdfluorescent protein) plasmid backbone. The mutant
protein was expressed in human cervix adenocarcinoma
(HeLa) and rat pituitary epithelial-like tumor (GH3) cell
lines, maintained in DMEM media supplemented with
10% fetal bovine serum, 20 mM L-glutamine, 100 units/ml
of penicillin G sodium, and 100 mg/ml streptomycin, or
F-12K medium supplemented with 15% horse serum, 2.5%
fetal bovine serum, 20 mM L-glutamine, 100 units/ml of
penicillin G sodium, and 100 mg/ml streptomycin, respect-
ively (Invitrogen). Transient transfections were carried
out as reported previously (7). For western blotting
and immunofluorescence analyses, the resulting vector
expressed the mutant P27 protein as a fusion protein with
the YFP tag at the N-terminus. Indirect immuno-
fluorescence was performed using a monoclonal anti-P27
antibody (BD Biosciences, San Jose, CA, USA) as reported
previously (7).Results
Case report
The relevant clinical details of the index case are briefly
reported. Primary hyperparathyroidism (PHPT) was firstly
diagnosed in the index case, a 41-year-old woman (serum
calcium 11.65 mg/dl (8.4–10.2 mg/dl) and parathyroid
hormone (PTH) 189 pg/ml (10–65 pg/ml)). In the same
year, she underwent inferior left and right parathyroidect-
omy (PTx). The two superior parathyroid glands appeared
normal at neck exploration and both were biopsied. The
histological examination of the inferior parathyroid
glands showed an oxyphil chief cells adenoma. The
biopsied superior parathyroid glands were histologically
normal. Serum calcium levels normalized after surgery and
no further biochemical testing was performed until the
age of 48 years when a relapse of PHPT was diagnosed
(serum calcium 11.3 mg/dl and PTH 201 pg/ml). Two years
later, at the age of 50 years, the patient was referred to
the Endocrine Unit of the University Hospital of Cagliari,
where she was followed from February 2007 to October
2011. The clinical and biochemical evaluation confirmed
the diagnosis of relapsing PHPT and the patient underwent
a second neck exploration. The superior right parathyroid
gland was removed and the histological examination
showed a 20 mm oxyphil chief cells adenoma. A search
for mutations of the MEN1 gene yielded negative results.
The subsequent follow-up was notable for the evidence
of gastro–entero–pancreatic NETs, which were initially
treated with proton-pump inhibitors and somatostatin
analogs, and then successfully by surgery. At follow-upThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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4–8 4 :4evaluation in October 2011, a relapse of PHPT was evident.
Total serum calcium and PTH were 10.6 mg/dl and
138 pg/ml respectively. A 99 m-Tc-Sestamibi scan showed
an uptake in the left paratracheal region. Anterior pituitary
function was normal and a pituitary MRI showed slight
enlargement of the left side of the gland, in the absence
of focal lesions. Surveillance was advised.
In April 2012, the patient was referred to the
University Hospital of Florence where in November 2012
the left superior parathyroid gland was removed and a
parathyroid fragment implanted in the non-dominant
forearm (29).Genetic analyses
The search for mutations in MEN1 in the entire coding
region and splice sites, previously performed, gave
negative results. This prompted us to search for mutations
of the CDKN1B gene and a novel germline heterozygous
deletion was found in exon 1 of the CDKN1B gene,
c.374_375delCT (according to the latest Human Genome
Variation Society nomenclature –http://www.hgvs.org/
mutnomen; the nucleotide numbering reflects coding
DNA, with C1 corresponding to the A of the ATG
translation initiation codon in the reference sequence).
The two-nucleotide deletion causes a frameshift in the
coding sequence, leading to a substitution of a serine
(TCT) with a stop codon (TGA) and the production of a
truncated P27 protein (S125X), consisting of 124 rather
than 198 amino acids of the WT protein. The P27_S125X
protein lacks the C-terminal domain, which contains
the NLS required to enter the nucleus where the protein
exerts its CDK-inhibitory function.
The proband’s tumoral parathyroid tissue did not
show allelic loss, because both WT and mutant alleles
were demonstrated to be present by sequencing the
somatic DNA. Genetic testing for the CDKN1B mutation
was advised to all first-degree relatives, but only one of the
three proband’s sons agreed to be investigated. The results
of the genetic test were negative.Figure 1
Immunohistochemical staining for P27. (A) Normal parathyroid gland from
a control individual. The parathyroid cells show a diffuse nuclear
immunoreactivity (!20). (B) Superior right parathyroid adenoma removed
at second parathyroidectomy from the MEN4 proband scored as negative
(!20). (C) Image obtained of a different area of the same section as (B)
showing a rim of normal parathyroid tissue (upper part of the image) with
a diffuse nuclear staining adjacent to the parathyroid adenoma (lower
part) (!20).Immunohistochemistry
A complete loss of nuclear P27 expression was observed
in the parathyroid tumor of the proband. The adjacent
normal parathyroid tissue showed strong nuclear staining
(the percentage of positive cells ranging between 50%
and 100%) similar to that observed in normal parathyroid
tissue. Representative images are shown in Fig. 1.http://www.endocrineconnections.org
DOI: 10.1530/EC-14-0116
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This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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5–8 4 :5Transfection studies
To determine the effect of mutation of human P27 on
protein localization, we generated WT P27 and P27_S125X
YFP-tagged proteins. The results of the western blotting
analysis indicated that the fusion proteins were expressed
at equal levels (Fig. 2A). As expected, the P27_S125X
protein was smaller as compared with the WT P27 fusion
protein. This phenomenon was reproducibly observed
in HeLa and GH3 cell lines and for independent DNA
clones of the same construct. We determined the cellular
localization of the fusion proteins by using an anti-YFP70 70
55
55
54
kDa
A
B
M
ol
ec
ul
ar
w
e
ig
ht
Ve
ct
or
P2
7_
W
T-
YF
P
P2
7_
S1
25
X-
YF
P
Ve
ct
or
P2
7_
W
T-
YF
P
P2
7_
S1
25
X-
YF
P
M
ol
ec
ul
ar
w
e
ig
ht
kDa kDakDa
P27
44
α-tubulin
α-tubulin
54
P27
44
55
25
55
HeLa cells
YFP DAPI YFP DAPI
YFP DAPI YFP DAPI
P27_WT
H
eL
a
G
H3
P27_S125X
GH3 cells
Figure 2
Expression and subcellular localization of exogenous proteins in HeLa and
GH3 cells transfected with the indicated constructs. GH3 cells do not express
endogenous P27. (A) Expression of proteins in transfected cells. 50 mg total
protein obtained from cell lysates were separated by electrophoresis,
blotted, and probed with YFP tagged-antibodies. Results from immuno-
blotting indicate that the fusion proteins are equally expressed. To control
for equal loading of lysates, the membrane was probed with the anti-
tubulin MAB. As expected, the P27_S125X protein, lacking 73 amino acids, is
approximately 10 kDa smaller as compared with the P27_WT fusion protein.
(B) Subcellular localization of YFP-tagged P27 proteins. Both HeLa (upper
panels) and GH3 (lower panels) cells were fixed 24 h after transfection
and nuclei were counterstained with 4 0,6-diamidino-2-phenylindole (DAPI).
The cells were examined for direct YFP fluorescence. P27_S125X localized
mainly in the cytoplasm, whereas P27_WT was in the nucleus.
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DOI: 10.1530/EC-14-0116
 2015 The authors
Published by Bioscientifica Ltdand indirect immunofluorescence. In both cell lines,
P27_WT localized in the nucleus, whereas the P27_S125X
protein was retained in the cytoplasm (Fig. 2B).Discussion
The medical history of the patient described herein
(multiglandular PHPT and multiple gastro–entero–pan-
creatic tumors) was consistent with the diagnosis of MEN1
syndrome, but unexpectedly, the genetic testing of the
MEN1 gene gave a negative result. The search for mutations
of other genes involved in parathyroid tumorigenesis
allowed the identification of a c.374_375delCT germline
mutation in the CDKN1B gene, leading to the diagnosis
of MEN4. The age at diagnosis of PHPT in our patient
(41 years), which was similar to those previously reported
for other MEN4 cases carrying nonsense or frameshift
mutations of CDKN1B (W76X and K25fs), was older
than the mean age of diagnosis of PHPT in patients with
MEN1 syndrome (25 years) (30), but younger than that of
MEN4 patients harboring missense (56 years) and 5 0UTR
mutations inCDKN1B (67 years) (31). No other phenotypic
differences were observed between patients with MEN4
carrying the c.374_375delCT truncating mutation or other
mutations of CDKN1B.
Herein we report the functional characterization of
the c.374_375delCTCDKN1B germline mutation. HeLa and
GH3cells transfectedwith theCDKN1BWTormutantcDNA
efficiently translated the constructs and the fusion proteins
were expressed at equal levels, as demonstrated by western
blotting analysis. The mutated protein was shorter (lacking
the last 74 amino acids) compared with the WT protein and
lacked the highly conserved C-terminal domain, which
includes the bipartite NLS (amino acids 152/153 and
166/168). This protein abnormality would be predicted to
result in its retention in the cytoplasm and loss of tumor-
suppressive function. In addition, the lack of the C-terminal
domain would also be predicted to result in the loss of the
binding domains of for some cytoplasmic interacting
partners of P27 involved in the regulation of cellular
functions independent of progression of the cell cycle,
such as differentiation and migration (Fig. 3). As a matter of
fact, the results of in vitro studies in HeLa cell lines indicated
that the P27_S125X protein was localized in the cytoplasm,
confirming that the mutant protein had lost its ability to
transfer into the nucleus. This in vitrophenotype is similar to
that of cells transfected with sequence encoding the W76X
nonsense variant found in the first MEN4 patient, affected
by PHPT and acromegaly (7). Notably, both the S125X and
the W76X mutations have previously been detected inThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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an adult T-cell leukemia/lymphoma, respectively, strength-
ening support for their role in tumorigenesis (17, 19).
Results from immunohistochemical studies were
indicative of a complete loss of nuclear expression of
P27 in the patient’s parathyroid adenoma. No staining
was evident in the cytoplasm. Conversely, a strong P27
staining was retained in a rim of normal parathyroid
tissue surrounding the adenoma. A reduction in P27
protein in a different parathyroid adenoma obtained
from the same patient at a later parathyroid surgery was
also observed (29). The same authors found significant
overexpression of CDKN1B mRNA compared with
CDKN1B-non-mutated parathyroid tumors and normal
parathyroid. The cDNA sequencing of the patient’s
tumoral mRNA revealed the presence of the WT, but not
the mutated mRNA. No explanation is given for the lack
of transcription of the mutated allele. The author’s
conclusion was that ‘in this case, the downregulation of
the P27 protein could be at a post-transcriptional and/or
post-translational level’. Only one study has previously
evaluated the sequence of mRNA in a renal angiomyoli-
poma and normal renal tissue from a patient with MEN4
harboring the W76X mutation (7). The authors found that
the WT and the W76X mutated alleles were equally
transcribed in both tissues, indicating that both alleles
were translated. This is in keeping with the results of
our in vitro studies, which indicated that the P27_S125X
mutant construct was fully translated into a truncated
protein.
The presence of a hemizygous deletion of the CDKN1B
gene in human hematopoietic malignancies, ovarian and
prostate cancers, associated with a reduced expression of
P27 is indicative of a CDKN1B haploinsufficient behaviorP27 WT
P27 S125X
1 25 90
90 96
1241
97
118
118
Figure 3
Schematic representation of WT and truncated P27_S125X protein. The
binding domains to major interacting partners of P27 are represented as
boxes filled with different patterns. Figures indicate the positions of the
first and the last amino acid of each domain. The truncated P27_S125X
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evidence of the role of P27 haploinsufficiency in the
development of cancer and may explain the later onset of
tumors in hemizygous compared with homozygous
deficient mice (23, 32).
Haploinsufficiency of CDKN1B has not been clearly
demonstrated in MEN4-associated tumors. Results of LOH
studies, using either microsatellites flanking CDKN1B or
sequencing the tumoral DNA, revealed allelic loss only
in two out of five MEN4-associated tumors (a bronchial
carcinoid and a small-cell neuroendocrine cervical
carcinoma) (8, 10), but not in a parathyroid adenoma
coexistent in the patient with bronchial carcinoid (10).
The complete loss of P27 protein according to immuno-
histochemistry in these LOH-positive tumors indicates
that CDKN1B behaves as a classical tumor suppressor
gene. Conversely, the reduced expression of P27 protein
in two of the three remaining LOH-negative tumors is
indicative of a haploinsufficient behavior. Finally, the lack
of P27 expression in the third LOH-negative case (W76X)
indicates that a second somatic hit, other than LOH,
inactivates the WT allele.
Both pathogenetic mechanisms (haploinsuffiency or
tumor-suppressor behavior) appear to be operating in
asynchronous parathyroid adenomas of the patient
described herein. Indeed, our finding of a complete loss
of P27 protein, in the absence of allelic loss, is indicative
of an alternative somatic hit (genetic or epigenetic) at the
CDKN1B locus. Conversely, the reduction in the level of
P27 protein observed in a previous study (29) in the absence
of allelic loss, is indicative of haploinsufficiency. This
observation is in keeping with the finding of different
somatic events in a patient with recurrent PHPT harboring a
germline CDC73 mutation (33). The positive P27 staining153 169
170 198
151 198
Cyclin-CDK binding domain
Proline-rich motif
Grb binding domain
RhoA binding domain
Stathmin binding domain
p38/Jab1 binding domain
Nuclear localisation signal
Rac-dependent cell migration
‘scatter domain’
198
158
protein lacks the C-terminal half of the protein, thereby loosing the nuclear
localization signal, and the binding sites for RhoA, Stathmin, and Rac-
dependent cell migration (also known as the ‘scatter domain’) and part of
the binding site of p38Jab1.
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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7–8 4 :7in the rim of normal tissue surrounding the parathyroid
adenoma in our patient provides strong support for the
occurrence of a second somatic hit at the CDKN1B locus.
In conclusion, our results reveal the pathogenic role
of the c.374_375delCT CDKN1B germline mutation in a
patient with MEN4. The absence of allelic loss and
complete lack of nuclear P27 expression in the parathyroid
adenoma indicate that a second somatic hit, other than
LOH, may inactivate the WT allele.Declaration of interest
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